Targeting the A2AR in cancer; early lessons from the clinic.
Curr Opin Pharmacol
; 53: 126-133, 2020 08.
Article
em En
| MEDLINE
| ID: mdl-33002857
ABSTRACT
The immunosuppressive tumor microenvironment (TME) represents a challenge that all immunotherapies must overcome to enable a robust and durable anti-tumor response. One of the dominant mechanisms of immunosuppression in the TME is hypoxia and the generation of extracellular adenosine [1]. Pioneering work from Drs Ohta and Sitkovsky demonstrating that adenosine signaling through the adenosine 2A receptor (A2AR) inhibits T cells has led to the development of several agents designed to inhibit the production or downstream signaling of adenosine [2â¢â¢,3â¢â¢]. This review will focus on the safety, efficacy, and biomarkers associated with A2AR antagonists in clinical development.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antagonistas do Receptor A2 de Adenosina
/
Neoplasias
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Pharmacol
Assunto da revista:
FARMACOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article